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Microbicided nucleic acid ligands (aptamers) that bind the surface envelope glycoprotein,
gp120, of HIV-1, and neutralize infection of diverse sub-types of virus. Our earlier studies have identiﬁed the
overall structure of one of these aptamers, B40, and have indicated that it binds to gp120 in a manner that
competes with that of the HIV-1 coreceptor, CCR5, and select “CD4i” antibodies with epitopes overlapping
this region. Here, we sought to map the B40 binding site on gp120 more precisely by analysing its interaction
with a panel of alanine substitution mutants of gp120. Furthermore, we tested our hypothesis concerning the
structure of the 40 nucleotide functional core of the aptamer by the solid-phase synthesis of truncated and
chemically modiﬁed derivatives. The results conﬁrm our structural predictions and demonstrate that
aptamer B40 neutralizes a diverse range of HIV-1 isolates as a result of binding to relatively conserved
residues on gp120 at the heart of the CCR5-binding site. These structural insights may provide the basis for
the development of potential anti-viral agents with high speciﬁcity and robustness.
© 2008 Elsevier Inc. All rights reserved.IntroductionHIV-1 entry is a multi-step process; the trimeric surface glycopro-
tein of HIV-1, gp120, binds to CD4 on the host cell surface, and
undergoes a conformational change enabling an interaction with the
alternative coreceptors, CCR5 or CXCR4. Thereafter, the viral and
cellular membranes fuse and the viral RNA enters the cell. Agents that
inhibit these processes might allow further investigation of the
molecular interactions involved, and also have potential as viral
therapeutics.
Accordingly, we have isolated nucleic acid ligands (aptamers) that
bind gp120, and thereby neutralize infection of virus (Khati et al.,
2003). The massively combinatorial library from which the aptamers
were selected comprised single stranded nucleic acids with 2′-F
pyrimidine and 2′-OH purine nucleotides, 117 nucleotides in length.
Aptamers were selected using an in vitro evolution method (ﬂow cell
SELEX) to bind to gp120 from a CCR5-utilizing strain of HIV-1 (BaL)proat@rna-tec.com (B. Sproat),
agee.edu (I. McGowan),
rsity of British Columbia, 675
l rights reserved.(Khati et al., 2003). Of over 60 monoclonal aptamers that bound to
gp120, more than 20 were able to neutralize HIV-1 infection of PBMC
cultures. Most interestingly, these aptamers were able to neutralize
clinical isolates of HIV-1 representing all sub-types, not just the
subtype B strain BaL against which they were selected (Khati et al.,
2003).
The RNA structure and mechanism of action of one such anti-
gp120 aptamer, B40, have been investigated in detail. Aptamer B40
RNA forms two alternative conformations in solution, and we have
hypothesized that it is the three-way junction structure rather than
the linear structure that binds to gp120 (Dey et al., 2005a). We had
previously noted partial competition between the binding of B40 and
monoclonal antibodies deﬁning the CD4i (CD4-induced) epitope
(Khati et al., 2003). Consistent with this, the aptamer competed
with a synthetic peptide corresponding to the N-terminus of CCR5 for
binding to gp120 (Dey et al., 2005b).
Here we sought to map the B40 binding site on gp120 (its
“aptatope”) more precisely by analysing its interaction with a panel of
alanine substitution mutants of gp120. A similar method has
previously been employed successfully to determine the epitopes of
a number of anti-gp120 antibodies (Darbha et al., 2004; Pantophlet et
al., 2003; Scanlan et al., 2002). Furthermore, we tested our hypothesis
concerning the structure of the 40 nucleotide (nt) functional core of
the aptamer by the solid-phase synthesis of truncated and chemically
47C. Cohen et al. / Virology 381 (2008) 46–54modiﬁed derivatives. Our results conﬁrm the structural predictions
and demonstrate that aptamer B40 neutralizes HIV-1 infectivity as a
result of binding to conserved residues of gp120 at the heart of the
binding site for the N-terminus of CCR5.
Results
Conﬁrmation of the branched structure of functional aptamer B40
Thermodynamic predictions suggest that both full-length aptamer
B40 and a 77 nt shortened derivative, B40t77, can exist in two
conformations – linear and branched – that are difﬁcult to distinguish
using low-resolution analysis with structure-sensitive nucleases. It
was important to deﬁne the functionally relevant conformers, in order
to guide the subsequent development of chemically synthesized
derivatives. Accordingly, we devised point mutants of B40t77
designed to bias the respective proportions of each conformer in the
aptamer population. Ideally a pair of mutations lying outside the
previously deﬁned gp120-binding site of the aptamer would beFig. 1. Conﬁrmation of the branched structure of functional aptamer B40t77. (a) Structu
conformations, and its mutant derivatives designed to adopt solely the linear (B40t77iii_4) or
by open arrows, together with the predicted free energy of each structure and double-heade
predicted using mfold. Unless otherwise stated, in this ﬁgure and elsewhere, all purine nuc
Representative BIAcore sensorgram overlay showing binding of aptamers B40t77 (solid line),
ﬁgures binding responses were normalized by subtracting the response from a blank ﬂowcel
is indicated by an arrow. (c) Aptamer-binding responses to gp120 obtained in (b). Here and su
the binding of parental aptamer B40t77 following subtraction of the response in the blank ﬂo
standard deviation of three replicates.chosen (Dey et al., 2005a), of which one favoured the folding of the
molecule into one conformer, and the second of which, a compensa-
tory mutation, would favour the alternative conformer. A large
number of mutational pairs were evaluated in silico, and of these,
three pairs appeared to meet the design requirements. When
evaluated for gp120 binding in vitro, two of these pairs proved to be
uninformative, as the ﬁrst mutation, which inactivated binding, was
not reverted phenotypically by the structure-correcting second
mutation (see Supplementary Fig. 1). In such cases, it is possible that
one or other of the mutations directly disrupted the aptamer-gp120
contact site, and so the effect on structure per se could not be
evaluated. The third pair of aptamers, B40t77iii_4 and B40t77iv_4, did
give decisive results (Fig. 1). Aptamer B40t77iii_4 contains an inserted
G after residue C35 that is predicted to stabilize the linear
conformation, and this aptamer bound poorly to gp120. Insertion of
an additional C residue after G28 in aptamer B40t77iii_4, to generate
aptamer B40t77iv_4 was predicted to stabilize the branched con-
formation, and gp120-binding was restored to wild-type levels. The
restoration of gp120-binding by a second mutation that compensatesres of aptamer B40t77, which is predicted to fold into both the linear or branched
branched (B40t77iv_4) conformation. The positions of nucleotide insertions are shown
d arrows indicating conformational interconversion. Structures and free energies were
leotides (G, A) have 2′-OH, and all pyrimidine nucleotides (U, C) are 2′-F modiﬁed. (b)
B40t77iii_4 (dashed line) and B40t77iv_4 (dotted line) to gp120. In this and subsequent
l, the duration of the injection is indicated by the horizontal bar and the 600 s time-point
bsequently responses observed 600 s after the start of injection are expressed relative to
w cell, and normalized for the molecular mass of each aptamer. Error bars represent the
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the branched conformer is the active form of the aptamer. Not only
have the mutations in B40t77iii_4 and B40t77iv_4 increased the
stability of the intended conformer, as shown by more negative free
energies compared to the same structure in B40t77, but also they have
decreased the stability of the alternative conformers, which are
energetically unfavourable. Nevertheless, we concede that within a
population of RNA molecules additional conformations may still exist,
and this could explainwhy only modest changes in binding were seen
with these aptamer derivatives compared to the parental aptamer
B40t77.Fig. 2. Binding of truncated aptamers to gp120. (a) Structures of synthetic aptamers based
energies are shown as predicted by mfold. Double-headed arrows indicate conformational i
247.6 and 299.2 are predicted to form just one each. In aptamer 247.6, open arrows mark th
arrowsmark the G:C insertion and the 2′-O-dimethylallyl residues are indicated bywhite lett
post-injection (see sensorgrams in Supplementary Fig. 2). All aptamers showed a statisticalChemical synthesis and stabilization of truncated aptamer B40 derivatives
As earlier foot printing results had indicated that the terminal stem
of aptamer B40 was not in contact with gp120, but simply required to
stabilize its structure, we undertook the design and synthesis of an
extensive series of derivatives of B40 in which we aimed to minimize
the size of this stem while maintaining its stabilizing effect (Fig. 2a).
The shortest derivative that we succeeded in producing by in vitro
transcription using T7 RNA polymerase, B40t77, possessed a stem 1
comprising 17 base pairs, interrupted by a single A bulge and an A:A
mismatch (Fig. 1). We used solid-phase synthesis to produceon B40t77 with truncations in the terminal stem. Predicted structures and their free
nterconversions. Note that 247.4 is predicted to form four principal structures, whereas
e positions of residues mutated with respect to aptamer 247.4. In aptamer 299.2, open
ers on black-ﬁlled circles. (b) Aptamer gp120-binding responses obtained by SPR at 600 s
ly signiﬁcant change in binding compared to B40t77 using a t-test (Pb0.005).
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reduced, and in which the interruptions to the stem were removed
(Fig. 2a). The data show that the terminal stem can be shortened
substantially while retaining good binding activity. However, once the
stability of the branched form drops relative to alternate conformers
by overly shortening the stem (indicated by an increased number of
structures predicted by mfold to have free energies within 5% of the
optimal structure), for example with aptamer 247.4, then binding
activity also drops (Fig. 2b). By introducing additional mutations into
the non-contact region of the internal 3-way junction loop of the
poorly binding derivative 247.4 (4 base pair stem 1), to generate
aptamer 247.6, we hypothesized that the multiple alternative
conformers that were predicted to exist in populations of the former
would be suppressed. This is supported by the mfold predictionwhich
only showed one structure for 247.6 with a free energy within 5% of
the optimal structure (Fig. 2b). The increase of gp120 binding resulting
from these mutations (Fig. 2b) conﬁrmed the functional importance of
the branched form.
In order to test whether alternative approaches to stabilizing the
short stem 1 of synthetic aptamer derivatives of B40 might result in
full restoration of binding activity, we took advantage of the properties
of 2′-O-dimethylallylribonucleotides (DMA; Iribarren et al., 1990;
Lamond and Sproat, 1993). This hydrophobic substitution has the
useful characteristic that it destabilizes duplexes when incorporated
into just one strand, but stabilizes them when incorporated on
opposite strands, presumably through hydrophobic interactions
across the minor groove of the A-form helix. We found that
incorporation of a total of six DMA nucleotides in stem 1, together
with the insertion of the additional base pair in stem 2 that stabilizes
the helix (aptamer 299.2) increased binding to above the levels seen
with B40t77 (Fig. 2b).Fig. 3. Binding of aptamer to mutants of gp120. Truncation mutants (b) and point mutants (
assay. In (b) the gp120 was pre-incubated in the presence or absence of CD4 prior to aptamer
wild-type gp120. Mutants whose binding is signiﬁcantly different from that of the wild-type
of less than 0.05, 0.01 and 0.001 respectively.Role of gp120 variable loops in aptatope exposure
We next sought to determine the aptamer-binding site (aptatope)
on gp120 using a novel aptamer-gp120 binding assay similar to an
ELISA. This method used aptamer 299.5 (Fig. 3a), a 5′-biotinylated
version of aptamer 247.6, chosen for its small size and gp120-binding
activity (see above). This aptamer was immobilized on a streptavidin-
coated plate and serial dilutions of gp120 mutants that were pre-
incubated with or without CD4 were added. Bound gp120 was
detected with antibody 2G12, which binds to the carbohydrate face of
gp120, a secondary HRP-conjugated anti-IgG, and a luminescent
substrate. Several optimizations were performed in order tomaximize
the sensitivity of the assay, and we were ﬁnally able to test the
aptamer binding to gp120 over a concentration range of four orders of
magnitude. Examples of binding curves are shown in Supplementary
Fig. 3.
Since earlier work had indicated that the aptamer-binding site
overlaps with the CCR5 binding site on gp120 (Dey et al., 2005b),
gp120 truncation and point mutants were selected that had
previously been shown to affect binding of CCR5, a sulfated N-
terminal CCR5 peptide, or CD4i antibodies 17b, 48d and X5 to gp120
(Cormier and Dragic, 2002; Cormier et al., 2001; Darbha et al., 2004;
Rizzuto and Sodroski, 2000; Rizzuto et al., 1998; Thali et al., 1993). Our
ﬁrst approach was to analyse aptamer binding to gp120 molecules
with truncations of three of the variable loops.
Fig. 3b shows the binding of aptamer 299.5 to gp120 truncation
mutants lacking the ﬁrst (ΔV1), ﬁrst and second (ΔV1/V2) or third
(ΔV3) variable loops, in the presence or absence of CD4 (Fig. 3b). The
EC50 of aptamer binding was signiﬁcantly lower to the ΔV1 and ΔV1/
V2 mutants compared to the wild-type gp120, indicating an increase
in relative binding, whereas the EC50 of aptamer binding to the ΔV3c) of gp120 were tested for binding to aptamer 299.5 (a) in an aptamer–gp120 binding
binding. EC50 values generated from binding curves are expressed relative to binding to
as determined by a t-test are indicated by asterisks, where ⁎, ⁎⁎ and ⁎⁎⁎ indicate p values
Fig. 4. Neutralization of HIV-1 by aptamer. The ability of aptamers B40 (Khati et al.,
2003), 299.2 (Fig. 2a) and UCLA1 (inset) to neutralize HIV-1 infection was tested in (a)
PBMCs and (b) BDMs isolated from three different donors. Each infection was carried
out in biological duplicates. Thirty-six hours post challenge, cellular DNA was
extracted and assayed by real-time qPCR for HIV-1 late reverse transcription products
and the human β-actin gene. These data were expressed as proviral DNA copies per
cell. Data from multiple donors, whose cells are found to vary in their susceptibility
to HIV-1, were combined by normalizing against the respective positive control
samples. Signiﬁcant neutralization, as determined by the t-test, is indicated as
follows: ⁎⁎(Pb0.01) or ⁎⁎⁎(Pb0.001).
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in relative binding. This pattern differs in important respects from that
seen in binding experiments using CD4i antibodies and CCR5. For
example, although the binding of antibody X5 is also increased by
truncation of V1 and V2 simultaneously, no effect is seen following
truncation of V1 alone (Labrijn et al., 2003; Moulard et al., 2002).
Moreover, truncation of V3 often does not affect the binding of CD4i
antibodies. Binding of the aptamer to these truncation mutants and
wild-type gp120 was unaffected by the addition of CD4 (Fig. 3b),
which again is in contrast to that of CCR5 and CD4i antibodies whose
binding to gp120 is enhanced by the addition of CD4 (Moulard et al.,
2002; Wyatt et al., 1995). These ﬁndings show that although the
variable loops of gp120 affect the accessibility of the B40 aptatope,
their relation to it differs from their relation the CD4i epitope and the
CCR5 binding site. Because removal of all three loops simultaneously
does not impair aptamer binding (Dey et al., 2005b), we conclude that
the aptatope lies largely within the gp120 core and that the V1 and V2
loops most likely occlude it, at least partially, in the native structure of
the envelope spike. As the effect of deleting V3 on aptamer binding is
different in the presence than in the absence of V1/V2, we could not
ﬁrmly conclude the putative role of V3 in aptamer binding using
truncated loops. Accordingly, we turned to a panel of single-point
gp120 mutants in order to deﬁne the aptamer-binding site more
precisely.
Deﬁnition of B40 aptatope using gp120 single-point mutants
Fig. 3c shows aptamer 299.5 binding to point mutants of gp120.
Four of the 19 mutants tested, T297S, R298A, K421A and I423A,
showed a signiﬁcant increase in EC50, corresponding to a decrease in
binding relative towild-type.We speculate that the positively charged
residues R298 and K421 interact with negatively charged backbone
phosphates of the aptamer. In the absence of a co-crystal structure of
gp120 with the aptamer, it is difﬁcult to speculate on the manner in
which the side chains of residues T297 and I423 are involved in the
interaction with the aptamer molecule. We do note that the
substantial reduction in binding of the aptamer to mutant I423A
indicates that the Ile is critical for the interaction, suggesting direct
interaction with the aptamer. Irrespective of the precise mode of
interaction, the identiﬁcation of all four residues as constituting the
aptatope provide important clues as to its cross-neutralizing activity
(Khati et al., 2003) and a comparison of how these residue
substitutions affect CD4i and CCR5 binding allows us to model the
aptatope relative to the binding sites of these other ligands. For
example, residue K421 is highly conserved amongst all primate
immunodeﬁciency viruses (Kwong et al., 1998); mutation of K421 to
alanine does not affect the binding of antibodies X5 or 17b, but does
decrease binding of 48d and CCR5 to gp120. Residue R298 binds to the
sulphated tyrosines in the N-terminus of CCR5 and is a critical residue
for the gp120–CCR5 interaction; mutation of R298 results in a loss of
CCR5 binding (Cormier et al., 2001; de Parseval et al., 2005; Rizzuto
and Sodroski, 2000) and also the binding of antibody X5 (Darbha et al.,
2004), but not 17b or 48d (Thali et al., 1993). Residue I423 is important
for the binding of antibodies X5and 17b to gp120 (Darbha et al., 2004;
Kwong et al., 1998), but is only somewhat important for CCR5 binding
(Rizzuto et al., 1998); whether this residue is important for 48d
binding has not been reported (Thali et al., 1993). These observations
are consistent with previous mapping studies that show contiguous
residues R419, I420, K421 and Q422 as highly important for CCR5
interaction with gp120 (Cormier et al., 2001; Rizzuto and Sodroski,
2000; Rizzuto et al., 1998). Residue T297 in gp120 was not tested in
previous studies that used gp120 mutants to map the CCR5, X5, 17b or
48d binding site (Cormier and Dragic, 2002; Cormier et al., 2001;
Darbha et al., 2004; Rizzuto and Sodroski, 2000; Rizzuto et al., 1998;
Thali et al., 1993). However, the recent structure of gp120 in complex
with the CD4i antibody 412d and docking models of the CCR5 N-terminus with gp120–CD4 indicate that residue T297 is unlikely to be
important for coreceptor binding (Huang et al., 2007).
Neutralization of HIV-1 infectivity by minimal aptamers
Although some short synthetic aptamers show an increase in
gp120 binding activity, when compared to the full-length B40 (see
above), it was necessary to test whether this is reﬂected in their ability
to limit HIV-1 infectivity. Accordingly, we compared the neutralization
activity of the parental aptamer, B40, with that of minimal aptamer
299.2 and a further derivative, UCLA1, inwhich there is, in addition, an
inverted thymidine at the 3′-end (to block degradation by 3′-
exonucleases) and a dimethoxyltrityloxy-(CH2)6-SS-(CH2)6-phospho
linker at the 5′-end (Fig. 4). These modiﬁcations were introduced in
order to increase the stability of the RNA to degradation by nucleases.
The neutralization activity of each aptamer was tested against HIV-
1BaL in both peripheral blood mononuclear cells (PBMCs) and blood
monocyte-derived macrophages (BDMs) at a ﬁnal concentration of
100 nM. We monitored HIV-1 neutralization after a single cycle of
infection by using quantitative PCR, which quantiﬁes the number of
copies of proviral DNA in each infected cell, in the presence and
Fig. 5. Aptamer-binding site. Location of gp120 residues important for B40 aptamer bindingmapped onto a V3-containing gp120 core structure derived from the primary isolate JR-FL
(Huang et al., 2005). Top panel: Surface rendering of gp120JR-FL core+V3 depicting residues identiﬁed by mutagenesis as important for CCR5 binding (cyan) (Cormier et al., 2001;
Rizzuto and Sodroski 2000; Rizzuto et al., 1998) and residues identiﬁed in this study by alanine mutagenesis that signiﬁcantly reduce aptamer binding (orange). The locations of the
V1/V2 stem, V3 and V4 are denoted for orientation purposes. Bottom panel: Ribbon model of gp120JR-FL+V3 depicting a close-up of the residues important for B40 binding (orange;
space-ﬁlling models).
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the aptamers was compared to the neutralizing monoclonal antibody
b12 (Burton et al., 1991) and the CCR5 antagonist, TAK 779 (Baba et al.,
1999).
Our results indicate that the parental aptamer, B40, reduces virus
infectivity by an average of 85% in PBMCs, the minimized aptamer
299.2 by 77%, and the closely-related derivative UCLA1 by 82%.
Interestingly, neutralization was generally less potent in BDMs, with a
similar but more noticeable order of potency between B40, 299.2 and
UCLA1 (70%, 56% and 84%, respectively). All neutralizations were
statistically signiﬁcant in relation to the aptamer-free control, but the
potency differences between aptamers did not reach statistical
signiﬁcance (Fig. 4).
Discussion
In this study we have demonstrated that the binding site of
aptamer 299.5 on gp120, and by extension we presume, that of the
parental aptamer B40, involves four key gp120 residues: K421, which
is conserved in all primate immunodeﬁciency viruses (Kwong et al.,
1998); R298, which is conserved in N99% of HIV-1 isolates (Kwong et
al., 1998); and T297 and I423, which are both moderately conserved
among HIV-1 isolates (Kwong et al., 1998). These data, in conjunction
with previous evidence (Dey et al., 2005b), indicate that the B40
aptatope on gp120 overlaps most closely with that of the CCR5 N-
terminus, thus, explaining the ability of this aptamer to block the
infectivity of a broad range of viral isolates. In order to obtain these
data, we generated a minimized, synthetic aptamer to serve as aligand for binding assays, and in doing so were able to conﬁrm the
secondary structure of the active form.
The B40 aptatope, as deﬁned here by alanine-scan mapping, is
illustrated in Fig. 5 in the context of the structure of a V3-containing
gp120 core (Huang et al., 2005). The aptatope overlaps with the
location of residues near the base of the V3 loop that have been shown
previously to be important for CCR5 binding (Cormier et al., 2001;
Rizzuto and Sodroski, 2000). Importantly, these results are in high
agreement with a docking model of the CCR5 N-terminus with a
recent CD4-complexed gp120 core structure (Huang et al., 2007). This
model suggests that the site of CCR5 N-terminus interaction is located
in a crevice formed at the base of the V3 loop with the gp120 bridging
sheet, which would partially overlap with the B40 aptatope and
indicates that the anti-viral activity of the B40 aptamer is due to
partial steric blockage of the CCR5 N-terminus–gp120 interaction. It is
perhaps worth noting here that while the B40 aptatope overlaps with
the interaction sites of CCR5 and CD4i antibodies such as 17b or X5, it
appears to involve fewer residues. We reason that this is because the
aptamer (17 kDa) is likely to have a smaller footprint on gp120 than
larger molecules such as CCR5 or an antibody. Moreover, in contrast to
these antibody epitopes and the CCR5-binding site, our data suggest
that the aptamer-binding site may be already fully formed on
unliganded gp120. This interpretation is consistent with the known
structure of unliganded SIV-1 surface glycoprotein (Chen et al., 2005)
but in the absence of equivalent data on HIV-1 gp120 (see review by
Pantophlet and Burton, 2006) our conclusionmust remain provisional.
The mapping of the aptamer-binding site to a core part of the
coreceptor-binding site provides a satisfying explanation for the
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(Khati et al., 2003). It was important to determine whether the short,
synthetic derivative aptamers, which had been used to accomplish
this mapping, retained the ability to inhibit virus infection. We tested
this possibility using a newly optimized neutralization assay involving
real-time PCR-based quantitation of proviral DNA produced during
the ﬁrst cellular infection cycle. We compared the activity of the full-
length (117 nt) aptamer B40, with two synthetic derivatives, 299.2
(54 nt) and UCLA1 (55 nt plus a bulky 5′ blocking group) that retain
full gp120-binding activity. While aptamer 299.2 exhibited lower
neutralization potency relative to B40, this was restored by the
addition of a bulky 5′-protecting group and an inverted nucleotide cap
at the 3′ in UCLA1.
The difﬁculties encountered in recent clinical trials of generic
microbicides have prompted a reinvestigation of the use of more
targeted anti-viral agents in microbicide strategies (Cohen, 2008;
Padma, 2008). It is possible that aptamers such as B40 and its
derivatives have potential in this regard, as they are exquisitely
targeted to the virus, while sharing the chemical composition of
already proven nucleic acid-based therapeutic agents such as
Macugen (for a review, see James, 2007). Furthermore, aptamers
may prove useful as molecular tools to study the HIV-1 entry process,
particularly conformational changes in the envelope spike.
Materials and methods
Synthesis of aptamer variants and in silico structural analysis
The sequences of the aptamers are given in Figs. 1–4. Unless
otherwise indicated, all purine nucleotides are standard ribonucleo-
tides and all pyrimidine nucleotides are 2′-F modiﬁed. Aptamers
B40t77iii_4 and B40t77iv_4 were synthesized by in vitro transcription
as previously described (Dey et al., 2005a). Synthetic aptamers were
produced by Integrated DNA Technologies, BVBA, Leuven by solid-
phase β-cyanoethylphosphoramidite chemistry on a 1 μmol scale,
except for UCLA1 which was synthesized on a 52 μmol scale. 5′-O-
Dimethoxytrityl-2′-O-dimethylallyl-N4-(4-tert-butylphenoxyacetyl)
cytidine-3′-O-(β-cyanoethylphosphoramidite and 5′-O-dimethoxytri-
tyl-2′-O-dimethylallyl-N2-(4-tert-butylphenoxyacetyl)-3′-O-(β-cya-
noethylphosphoramidite) were custom synthesized by SAFC Proligo
(Hamburg). 5′-O-Dimethoxytrityl-N(tac)-2′-O-TBDMS-3′-O-(β-cya-
noethylphosphoramidites) of A and G and 5′-O-dimethoxytrityl-2′-
ﬂuoro-2′-deoxy-N4-acetylcytidine-3′-O-(β-cyanoethylphosphorami-
dite) and 5′-O-dimethoxytrityl-2′-ﬂuoro-2′-deoxyuridine-3′-O-(β-
cyanoethylphosphoramidite) were obtained from SAFC Proligo. Poly-
styrene based solid-phase RNA supports were from GE Healthcare.
The thiol-modiﬁer C6 S-S CE phosphoramidite used at the 5′-terminus
of UCLA1 was obtained from Glen Research. The synthesis of UCLA1
was performed on an inverted dT polystyrene support loaded at
40 μmol/g, which was obtained from GE Healthcare.
The aptamers were all synthesized “trityl-on” using 5-benzylmer-
capto-1H-tetrazole as coupling agent following previously described
methods (Sproat, 2005) with some minor modiﬁcations. The
deprotection of the support was performed with anhydrous 7 M
methanolic ammonia for 12 h at room temperature followed by 3 h at
65 °C. When cool the supernatant was removed by ﬁltration, the
support was washed 3 times with sterile ethanol/water (1:1 v/v) and
the combined supernatants were dried in vacuo at a temperature
below 30 °C. Subsequently the standard “trityl-on” desilylation
protocol was employed. The precipitated fully deprotected, still
“trityl-on” aptamers were puriﬁed by reversed phase HPLC and then
detritylated, except for UCLA1. UCLA1 was puriﬁed on a Source 15 RPC
FineLINE 35 column eluted with a gradient of acetonitrile in aqueous
0.1 M ammonium bicarbonate. After desalting and removal of solvent
in vacuo all aptamers were repuriﬁed and simultaneously converted to
their sodium salts by anion-exchange HPLC on Source 15Q, elutingwith a linear gradient of aqueous sodium perchlorate. The desired
product peaks were desalted by gel ﬁltration and lyophilized. QC was
performed by analytical anion-exchange HPLC on a DNAPac PA200,
4×250mm column (Dionex) and by reversed phase HPLC on an XTerra
RP8 5 μm, 4.6×250 mm column (Waters) and the desired aptamer
mass was conﬁrmed by electrospray mass spectroscopy.
The mfold algorithm (Zuker, 2003), implemented on the Rensse-
laer bioinformatics web server (http://mfold.bioinfo.rpi.edu/) was
used to predict optimal and sub-optimal secondary structures and
their free energy values for the aptamer sequences. We have
previously found the standard parameters adequate to predict the
empirically veriﬁed structures of aptamer B40 (Dey et al., 2005a).
SPR binding assays
Aptamer binding to gp120 by BIAcore surface plasmon resonance
(SPR) was performed essentially as described (Dey et al., 2005a,
2005b). Approximately 5000 U of gp120 were coupled to the surface
of ﬂow cell 1 of a CM5 chip using amine coupling chemistry, and ﬂow
cell 2 was left blank as a control. Aptamers were refolded in CHBS
buffer at 1 μM and were injected over ﬂow cells 1 and 2 for 7 min at
5 μL/min, then allowed to dissociate for 10 min. The chip was
regenerated by injection of 5 μL 10 mM NaOH then ﬂow of buffer for
10 min, and this did not affect subsequent aptamer binding (data not
shown). Each aptamer was injected three times and the order of
injection was randomized. Analysis was performed using BIAevalua-
tion software and the binding response at 600 s, following subtraction
of the curve from the control ﬂow cell, was noted. This time-point was
chosen to coincide with maximal aptamer binding just after the
injectionwas completed. Since SPR response correlates with molecule
size, the aptamer-binding responses were normalized for the aptamer
molecular mass and are expressed as binding relative to B40t77,
where B40t77 response was normalized to 1 for each set of
experiments. As earlier attempts to obtain detailed kinetic data of
aptamer–gp120 binding by SPR were unsuccessful, we pursued the
semi-quantitative approach described above.
Generation of wild-type and mutant gp120 s
Expression of HIV-1BaL gp120 from a baculovirus vector in Sf9
insect cells was performed as described (Dey et al., 2005a, 2005b).
Additional recombinant HIV-1BaL gp120 was obtained from the AIDS
Research and Reference Reagent Program, National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda, MD
(NIH ARRRP) (#4961).
HIV-1 particles competent for a single round of infection and
pseudotyped with JR-CSF Env containing truncation or point muta-
tions were generated as described previously (Pantophlet et al.,
2003). 293T cells were transiently transfected with pNL4.3.Luc.R−.E−
and pSVIII-Env using FuGENE 6 (Roche), according to the manufac-
turer's instructions. After 48 h, viral particles were lysed with the
addition of 1% Empigen to supernatants. The concentration of gp120
in pseudovirus samples was estimated by quantitative Western blot
detected with monoclonal antibody 2G12 (NIH ARRRP) at 1 μg/mL
and peroxidase-conjugated anti-human IgG secondary antibody
(Sigma) and developed by enhanced chemiluminescence (GE Health-
care). The ﬁlm was used to generate an electronic image and sample
concentrations were estimated according to band density in
comparison to standards, using ImageQuant™ software version 5.2
(GE Healthcare).
Aptamer–gp120 binding assay
A novel binding assay was developed in order to investigate the
interaction of aptamer 299.5 (a 5′-biotinylated, synthetic derivative of
B40, see Fig. 3a) with various gp120 mutants. All steps were
53C. Cohen et al. / Virology 381 (2008) 46–54performed at room temperature except where indicated, reaction
volumes were 100 μL, and 3–5 washes with 0.05% Tween-20 in PBS
were performed between the addition of each reagent. Aptamer 299.5
was refolded as previously described (Dey et al., 2005a) in CHBS buffer
to a ﬁnal concentration of 100 nM and was added to Reacti-bind HBC
streptavidin-coated 96-well plates (Pierce) for 30 min. A blocking
solution of 0.8 μM biotin and 1% BSA in PBS was added for 30 min.
Serially-diluted pseudovirus-derived gp120 was pre-incubated in the
presence or absence of 100 nM soluble hCD4 for 1 h at 37 °C, and then
added to the reaction plate for at least 2 h. Gp120 was detected with
antibody 2G12 at 1 μg/mL in CHBS for 1 h followed by HRP-conjugated
anti-human IgG (Sigma) diluted 1/1000 in CHBS for 1 h. Aptamer–
gp120 interaction was detected by the addition of SuperSignal
luminescent substrate (Pierce) andwas recorded using a luminometer.
Luminescence was plotted against the log of gp120 concentration and
binding was modeled on a sigmoidal dose–response curve using
GraphPad Prism (GraphPad Software, Inc. CA). From this model EC50
values were obtained for each mutant, and these values were
transformed using (EC50mutant/EC50WT) to calculate binding relative
to wild-type. Each Env mutant was analyzed in at least two
independent assays.
Cultivation of human PBMCs and BDMs
Peripheral blood mononuclear cells (PBMCs) and blood monocyte-
derived macrophages (BDMs) were isolated by Ficoll-Hypaque
(Pharmacia-Amersham) density gradient centrifugation from hepar-
inized buffy coats of normal, HIV-negative donors. The diluted,
autologous plasma was saved, heat-inactivated, and clariﬁed to
provide autologous serum (AS) supplement for the culture. The
PBMCs were washed six times in PBS (Sigma) at 4 °C and were
essentially free of platelets and granulocytes. PBMC cultures were
cultivated without mitogen-activation or exogenous interleukin-2 (IL-
2). The cells were maintained in X-VIVO 10 (BioWhittaker) containing
2% AS. BDMs were isolated by CD14+ selection using anti-CD14
magnetic beads (Miltenyi Biotec Ltd.) according to the manufacturer's
protocol. CD14+ cells were then plated in 12-well plates at a density of
5×105 cells/well. These cells were cultured for 7 days in RPMI 1640
media supplemented with 10% FCS and 50 ng/ml of recombinant
human M-CSF (R&D Systems) growth factor until they were fully
attached and differentiated into macrophages.
Virus stock
HIV-1BaL strain used in this study was obtained through the NIH
ARRRP AIDS Research and Reference Reagent Program, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, MD. Virus was grown in human PBMC cultures,
harvested and centrifuged at 3000 rpm for 5 min to remove any
cellular debris. The collected supernatant was then ﬁltered through a
0.45 μm ﬁlter, and treated with DNase I (Sigma-Aldrich) to remove any
traces of cellular DNA. Aliquots were stored at −130 °C.
Neutralization assays
RNA aptamers (1 μM in CHBS) were refolded as previously
described (Dey et al., 2005a) and kept on ice. Virus (HIV-1BaL; 105
infectious units/mL) was incubated with aptamer (100 nM) for 45 min
at room temperature in a total volume of 500 μL. Positive neutraliza-
tion control was the neutralizing anti-gp120 monoclonal antibody,
b12 (Burton et al., 1991) (reagent #2640 from the NIH ARRRP; 10 μg/
mL). For comparison, the CCR5 antagonist, TAK 779 (Baba et al., 1999)
(reagent #4983 from the NIH ARRRP; 300 nM) was pre-incubated
with target cells for 1 h before virus challenge.
PBMCs and BDMs were infected in 12-well plates with 500 μL of
DNase I-treated HIV-1BaL in the presence or absence of inhibitor. Viruswas spinoculated onto the cells by centrifugation at 2000×g for
90 min at 4 °C. Cells were then incubated for a further 30 min at 37 °C,
before removal of the inoculum and replacement with fresh media.
The infections were left to proceed for 36 h, after which the cells were
harvested by scraping. DNA was extracted using DNeasy Blood and
Tissue Kit (Qiagen) according to the manufacturer's instructions. Real-
time PCR using primers MH531 and MH532, and the ﬂuorescent
probe, LRT-P (Butler, Hansen, and Bushman, 2001), was used to
quantify late stage HIV-1 reverse transcripts. The conditions for qPCR
comprised forty cycles, each comprising 1.5 min annealing and
extension at 58 °C. In parallel, real-time PCR quantitation of the host
gene, β-actin was performed using the control kit, RT-CKYD-ACTB
(Eurogentec) in order to normalize for cell numbers. Quantitative PCR
master mix and methods were from Eurogentec, and equipment from
MJ Research (Chromo4™ PTC-200).
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